


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
OPDUALAG is a sterile, preservative-free solution for intravenous infusion containing two monoclonal antibodies: nivolumab, a PD-1 blocking antibody, and relatlimab, a LAG-3 blocking antibody.
This dual mechanism of action works by inhibiting two distinct immune checkpoints, thereby enhancing T-cell activation and promoting an anti-tumor immune response. It is indicated for adult and pediatric patients 12 years and older weighing at least 40 kg with unresectable or metastatic melanoma.
Treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Examples include allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides when the benefit of reducing edema and inflammation is deemed to outweigh the risks.
Shake the bottle vigorously before each use.
For Steroid-Responsive Diseases: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) four times daily. Dosing may be increased to one drop every hour during the initial treatment period if necessary.
For Post-Operative Inflammation: Instill 1 to 2 drops into the conjunctival sac of the operated eye(s) four times daily, starting 24 hours after surgery and continuing through the first two postoperative weeks.
